FHL2 expression and variants in hypertrophic cardiomyopathy
Felix W. Friedrich(Universität Hamburg), Lucie Carrier(Universität Hamburg), Jolanda van der Velden(Amsterdam University Medical Centers), Thomas Eschenhagen(Universität Hamburg), Richard Isnard(Fondation pour l’innovation en Cadiométabolisme et Nutrition), Philippe Charron(Inserm), Enrique Galve(Vall d'Hebron Hospital Universitari), Aileen Schwalm(Universität Hamburg), Julia Münch, Wolfgang A. Linke(University Hospital Münster), Oliver J. Müller(University Hospital Schleswig-Holstein), Stefan Engelhardt(Heidelberg University), Pascale Richard(University Medical Center Groningen), Monica Patten(Universität Hamburg), Silke Reischmann(Universität Hamburg), Deepak Ramanujam(Technical University of Munich), Andreas Unger(Ruhr University Bochum), Christian Hengstenberg(Medical University of Vienna)
Cited by 71
Related Papers
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
|Nature|2008|2.4k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy
|Journal of Clinical Investigation|2014|993
MicroRNAs in the Human Heart
|Circulation|2007|888